AKESOgen’s management team is drawn from the US, Europe and Canada. The team has considerable expertise leading and managing organizations and groups in large corporations, academia, small biotech companies and governmental organizations.
Get to know the leaders of AKESOgen and learn about their history of success.
Robert Boisjoli FCPA, FCA, CBV, is a founder of AKESOgen and has served as Chief Executive Officer since the inception of the company.
Mr. Boisjoli is also a partner at Atwater Financial Group since 2003, a merchant-bank investor that provides a combination of investment banking and consultancy services. From 2008 to early 2010, he was Chief Financial Officer of Topigen Pharmaceutical Inc. until its sale in February 2010 to Pharmaxis, an Australian based biopharmaceutical company. From 2001 until 2008, Mr. Boisjoli was the Chief Financial Officer, Chief Operating Officer and co-founder of Xanthus Pharmaceuticals, Inc. until its sale in June 2008 to Antisoma PLC, a UK based biopharmaceutical company.
Mr. Boisjoli is a Fellow Professional Chartered Accountant (FCPA, CPA) and a Chartered Business Valuator (CBV) having obtained a Bachelor of Commerce and Diploma in Accounting at Concordia University.
Mark Bouzyk Ph.D. is a founder of AKESOgen and has served as Chief Scientific Officer since the inception of the company.
Dr. Bouzyk was a Director of the Emory Biomarker Service Center (EBSC), Director, Basic Research Shared Core Resources, Emory Winship Cancer Institute, Emory University as well as Director of the Center for Medical Genomics at Emory University, Atlanta. These facilities were developed by Dr. Bouzyk as state of the art laboratory capabilities to enable high throughput genetic, genomic and microarray biomarker studies ranging from DNA, copy number variation, expression, miRNA and methylation profiling all supported by a robust and flexible data management infrastructure in a Clinical Laboratory Improvement Amendments (CLIA) environment. In addition, to help meet the increasing need for translational medicine solutions and by working closely with other laboratories he developed an infrastructure which provides faster, more cost efficient and streamlined genetic tests using rapidly advancing genetic technologies in a clinical environment. Prior to joining Emory Dr. Bouzyk spent approximately 9 years in a global pharmaceutical company, GlaxoSmithKline, where he served as Director of Genetic Laboratory Sciences leading the company’s high throughput genomic efforts in Europe. Dr. Bouzyk’s interests lie in Pharmacogenetics as well as candidate gene and genomic association studies to identify susceptibility genes for both common and rare diseases particularly in the areas of Oncology, Cardiology, Neurological and Psychiatric disorders.
Dr. Bouzyk holds a Ph.D. in Human Molecular Genetics from University of Hertfordshire and a Bachelor of Science with Honors in Biochemistry from University College London.
Gabriela Oprea-llies M.D. has been with AKESOgen since 2012, and is now serving as Laboratory Medical Director.
Dr. Oprea-Ilies has provided pathology and cytology services for more than twelver years at Emory University Hospital and Grady Memorial Hospital that averages 15,000 surgical and 30,000 cytology specimens/year, with active FNA clinic involvement. Her current interest relates to carcinogenesis, in general with emphasis on breast cancer. Other interests include the effect of HIV infection, from reactive to neoplastic, on different organs and systems and the interplay with other viral infections as related to carcinogenesis.
Dr. Oprea-Ilies, M.D., received her doctoral degree from the Institute of Medicine and Pharmacy, Tirgu-Mures Romania and was a resident in Obstetrics-Gynaecology at the Institute of Medicine and Pharmacy Cantacuzino in Bucharest, Romania. She is Board Certified in Anatomic and Clinical Pathology and in Cytopathology. She completed her residency and fellowship in Pathology, at the University of Minnesota, and fellowship in Cytopathology at Emory University.
Barbara Glazer M.T. (ASCP), has been with AKESOgen since 2014 and is now serving as Director, Compliance & Clinical Trial Project Management. Ms. Glazer graduated from the University of Pittsburgh and has had a career as a laboratorian, building on experience in hospital and reference laboratories to move into clinical trials project management and operations management where she served for 17 years at Quintiles Laboratories.
Ms. Glazer led one of the first biobanks to achieve College of American Pathologists (CAP) accreditation for biorepositories and is a member of the International Society for Biological and Environmental Repositories (ISBER) and the Biospecimen Science working group. Ms. Glazer’s presentations have included Quality Management Systems shipping and logistics of biological samples, among others. Additionally, she is Chair of the Advisory Board at Atlanta Technical College Bioscience Technology.Share this